Authors
Latest:
Operationalizing TAR-200 and Other Delivery Systems in PracticeExperts discuss whether novel delivery systems in non–muscle-invasive bladder cancer (NMIBC) could be easily adopted in clinical practice and the challenges they anticipate in operationalizing TAR-200 and other novel delivery systems in urology practices.
Latest:
Jeremie Calais, MD, on development of a prostate cancer imaging reporting template“It encompasses and contains the miTNM, PROMISE, PRIMARY, RECIP, PSMA-RADS, and E-PSMA concept and criteria all together,” says Jeremie Calais, MD, PhD.
Latest:
iRARC adoption is slow but persistent in bladder cancer"Over the past 10 to 15 years, tremendous efforts have gone into robotic surgical innovation to improve perioperative morbidity for patients with bladder cancer undergoing RC," write Andrew M. Wood, MD, and Nima Almassi, MD.
Latest:
Post-surgery nivolumab boosts disease-free survival in muscle-invasive urothelial carcinomaAdjuvant treatment with the anti–PD-1 immunotherapy significantly extended the time period after primary treatment in which patients had no signs or symptoms of cancer.
Latest:
Race-based adjustment of eGFR: Current opinions and impact on urologic oncology“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.
Latest:
Talazoparib/enzalutamide significantly boosts OS in mCRPC"The TALAPRO-2 results provide much-needed hope to patients who remain in high unmet need for effective treatment options," said Neeraj Agarwal, MD, FASCO.
Latest:
Testosterone therapy and prostate cancer: Risk-benefit and individualized treatment“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH.
Latest:
Reimplantation of Tibial Nerve Stimulation Device (eCoin)OAB experts share their experience with reimplantation of a tibial nerve stimulation device (eCoin).
Latest:
18F-flotufolastat PET alters treatment approach for nearly 90% of patients with recurrent prostate cancer“Treatment based on visualization of 18F-flotufolastat–avid lesions may facilitate optimal targeting of recurrence sites and avoid futile salvage therapy,” said Przemyslaw Twardowski, MD.
Latest:
Future Directions in mCRPCPanelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while emphasizing the importance of ongoing education for community oncologists to stay updated on these changes.
Latest:
Physician highlights AI’s potential to improve practice efficiency and alleviate burnoutArtificial intelligence can help curate, decipher, and contextualize the enormous and growing amount of digital data that now comprises a patient’s electronic health record, writes Nele Jessel, MD.
Latest:
How the SECURE Act affects inherited IRAsLegislation sets 10-year withdrawal window for nonspouse beneficiaries.
Latest:
The evolving role of microRNAs in testicular cancer management"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.
Latest:
CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC"The updated results from CLEAR trial confirming that the amount of tumor shrinkage correlates with prognosis through overall survival, PFS, as well as through IMDC prognostic scoring should add further weight to lenvatinib and pembrolizumab being a go-to standard of care in this setting," says Thomas E. Hutson, DO, PharmD.
Latest:
2024 Urology Times pipeline reportCatch up on all the notable drug and device approvals in urology over the past year.
Latest:
Dr. Schwen on focal therapies for prostate cancerZeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Latest:
Future Directions for Imaging and Biopsy in Prostate CancerThe panel offers key takeaways on the evolving landscape for imaging and biopsy in prostate cancer, highlighting the role for fusion-guided biopsy in the diagnosis and management of prostate cancer.
Latest:
Artificial intelligence is the new ghost author in urological research“Although the future of AI within science is uncertain, disclosure of the use of AI is an excellent first step to balance academic integrity with disruptive innovation,” the authors write.
Latest:
Nivolumab/Cabozantinib combo continues to show HRQOL benefit in renal cell carcinomaLong-term follow-up from the CheckMate 9ER trial continued to show that first-line treatment with nivolumab plus cabozantinib was associated with a health-related quality-of-life benefit over treatment with sunitinib in patients with advanced renal cell carcinoma .
Latest:
Thomas Mueller, MD, on the removal of residual stone fragments“The 1 main assumption that we've been very wrong on although we've had the data for a long period of time, [is that] although we assume that the stone fragments are small enough to pass, oftentimes they don't,” says Thomas Mueller, MD.
Latest:
Suffering from Bladder or Pelvic Floor Issues? Here’s How a Urogynecologist Can HelpUrogynecologists focus on female pelvic medicine and reconstructive surgery, handling issues related to the pelvic floor and bladder.
Latest:
Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBCThe trial is assessing the safety and tolerability of adaptive radiation therapy with concurrent sacituzumab govitecan in patients with MIBC.
Latest:
Key Trials on PARP Inhibitor Combinations in Metastatic Prostate Cancer: Efficacy and Future ConsiderationsPanelists discuss how the increased use of androgen receptor–targeted therapy in clinical practice may impact the effectiveness of PARP inhibitor combinations like talazoparib in the TALAPRO-2 study, while also addressing safety concerns, potential differences in trial populations, and the need for future studies to optimize treatment approaches for various metastatic prostate cancer patient subgroups.
Latest:
Michelle Sheng, MD, on strategies to improve female representation in urology“I think promoting women in leadership positions, promoting mentorship for women applicants and women already in this field, and working on policy changes are the top 3,” says Michelle S. Sheng, MD.
Latest:
Novel FGFR2/3 inhibitor shows promise in solid tumors, including bladder cancerThe novel agent ABSK061 approached a response rate of 40% in patients with advanced solid tumors harboring FGFR2/3 alterations.
Latest:
Operationalizing TAR-200 and Other Delivery Systems in PracticeExperts discuss whether novel delivery systems in non–muscle-invasive bladder cancer (NMIBC) could be easily adopted in clinical practice and the challenges they anticipate in operationalizing TAR-200 and other novel delivery systems in urology practices.
Latest:
Joy Maulik, CRNP, on the growing role of PARP inhibitors in prostate cancer“When a patient knows that there are so many tools that are there for people, it gives them hope. It gives their caregivers hope,” says Joy Maulik, CRNP.
Latest:
Scott Tagawa, MD, highlights phase 3 trial of 177Lu-TLX591 in mCRPCProstACT GLOBAL is assessing the safety and efficacy of 177Lu-TLX591 plus SOC vs SOC alone in patients with mCRPC.
Latest:
Is your practice equipped to battle ransomware attacks?3 steps to protect your practice from ransomware.
